Late Breaking Abstract - Rituximab limits the progression of fibrosing mediastinitis

Conclusion: In young patients with progressive FM, we present the first prospective off-label use of Rituximab to limit disease progression based on imaging and clinical parameters.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Varghese, C., Johnson, G., Eiken, P., Tobias, P. Tags: Clinical Problems Source Type: research